| Name | MCP110 |
| Description | MCP110 is an inhibitor of the interaction of Ras with Raf-1 and can be used in studies about the treatment of human tumors. |
| In vitro | In A549 cells, MCP110 (20 μM) decreases Ras stimulation of Raf-1 and cyclin D level stimulated by the treatment with EGF (100 ng/mL), platelet-derived growth factor (20 ng/mL), and serum. In in HEK293 cells, MCP110 (10 and 20 μM) inhibits H-Ras (V12)-induced AP-1 activation. In fibrosarcoma HT1080 cells, MCP110 (1, 2, 5, 10, and 20 μM) shows a dose-dependent inhibition of elevated Raf-1 activity[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pure form: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (9.83 mM), Sonication is recommended.
DMSO : 245 mg/mL (481.67 mM), Sonication is recommended.
|
| Keywords | Ras | Raf-1 | Raf kinases | Raf | MCP110 | Inhibitor | inhibit | colorectal | cancer | astrocytomas |
| Inhibitors Related | Adagrasib | Regorafenib monohydrate | RMC-9805 | Vemurafenib | Sorafenib | (R)-Naproxen | Ketoconazole | MRTX1133 | Regorafenib | Dabrafenib | Sotorasib | Daraxonrasib |
| Related Compound Libraries | Anti-Colorectal Cancer Compound Library | Reprogramming Compound Library | Bioactive Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Inhibitor Library | Stem Cell Differentiation Compound Library | PPI Inhibitor Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | GPCR Compound Library |
United States
